Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phio Pharmaceuticals Corp PHIO

Healthcare Biotechnology
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or... see more

Recent & Breaking News (NDAQ:PHIO)

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

PR Newswire May 2, 2022

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma

PR Newswire April 26, 2022

Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer

PR Newswire April 18, 2022

Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022

PR Newswire April 8, 2022

Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update

PR Newswire March 22, 2022

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022

PR Newswire March 8, 2022

Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

PR Newswire February 22, 2022

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

PR Newswire January 11, 2022

Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference

PR Newswire January 3, 2022

Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting

PR Newswire November 12, 2021

Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

PR Newswire November 10, 2021

Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

PR Newswire October 18, 2021

Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PR Newswire October 7, 2021

Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021

PR Newswire September 30, 2021

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

PR Newswire September 16, 2021

Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th

PR Newswire September 3, 2021

Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021

PR Newswire August 31, 2021

Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

PR Newswire August 12, 2021

Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th

PR Newswire July 7, 2021

Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th

PR Newswire June 22, 2021